Literature DB >> 15837601

Strategies for producing faster acting antidepressants.

Albert Adell1, Elena Castro, Pau Celada, Analéa Bortolozzi, Angel Pazos, Francesc Artigas.   

Abstract

Existing antidepressant treatments exhibit limited efficacy and a slow onset of action. Several neurobiological adaptive mechanisms might delay the clinical effects of antidepressants, whose therapeutic action is primarily triggered by an increase of serotonergic and noradrenergic neurotransmission. Here, we review several potential mechanisms that could be useful to increase the speed of current antidepressant drugs, such as additional blockade of aminergic autoreceptors or antagonism of certain postsynaptic (5-HT2A, 5-HT2C) receptors. The potential use of strategies not based on monoaminergic transmission, such as CRF and NK1 receptor antagonists, or more novel strategies, based on glutamatergic or GABAergic transmission or on intracellular messengers, are also reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837601     DOI: 10.1016/S1359-6446(05)03398-2

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  32 in total

1.  Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant.

Authors:  C E Beyer; Q Lin; B Platt; J Malberg; G Hornby; K M Sullivan; D L Smith; T Lock; P J Mitchell; N T Hatzenbuhler; D A Evrard; B L Harrison; R Magolda; M N Pangalos; L E Schechter; S Rosenzweig-Lipson; T H Andree
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

2.  Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Maryka Quik; Archana Mallela; Jason Ly; Danhui Zhang
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

3.  Behavioral and biochemical effects of ketamine and dextromethorphan relative to its antidepressant-like effects in Swiss Webster mice.

Authors:  Linda Nguyen; Brandon P Lucke-Wold; Aric F Logsdon; Anna L Scandinaro; Jason D Huber; Rae R Matsumoto
Journal:  Neuroreport       Date:  2016-09-28       Impact factor: 1.837

4.  Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.

Authors:  Christoph van Amsterdam; Christoph A Seyfried
Journal:  Psychopharmacology (Berl)       Date:  2014-01-14       Impact factor: 4.530

5.  A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment.

Authors:  Emmanuel Stip; Adel Cherbal; David Luck; Simon Zhornitsky; Lahcen Ait Bentaleb; Ovidiu Lungu
Journal:  Psychopharmacology (Berl)       Date:  2017-02-17       Impact factor: 4.530

6.  Differential role of 5-HT1A and 5-HT1B receptors on the antinociceptive and antidepressant effect of tramadol in mice.

Authors:  Esther Berrocoso; M Olga Rojas-Corrales; Juan A Mico
Journal:  Psychopharmacology (Berl)       Date:  2006-07-11       Impact factor: 4.530

7.  The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus.

Authors:  Smita Thakker-Varia; Jennifer Jernstedt Krol; Jacob Nettleton; Parizad M Bilimoria; Debra A Bangasser; Tracey J Shors; Ira B Black; Janet Alder
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

Review 8.  Neuropeptides in depression: role of VGF.

Authors:  Smita Thakker-Varia; Janet Alder
Journal:  Behav Brain Res       Date:  2008-10-15       Impact factor: 3.332

Review 9.  Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.

Authors:  Lee A Dawson; Jeannette M Watson
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

10.  Region-specific regulation of 5-HT1B receptors in the rat brain by chronic venlafaxine treatment.

Authors:  R Vidal; A Diaz; A Pazos; E Castro
Journal:  Psychopharmacology (Berl)       Date:  2013-04-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.